You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
迪安診斷(300244.SZ)半年度淨利潤預增33.64%-53.58%
格隆匯 07-12 18:48

格隆匯7月12日丨迪安診斷(300244.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨利潤6.7億元-7.7億元,同比增長33.64%-53.58%。

報吿期內,雖然全國診療人次較2019年有明顯下降,剔除新冠業務增量,公司傳統檢驗業務和產品業務較2019年同期收入和利潤呈現高質量增長態勢。契合醫改形勢下醫療機構的新需求趨勢,公司更加堅定醫學診斷整體化解決方案的獨特競爭優勢,以臨牀和疾病為導向,加強學科和技術平台建設,大力推進以精準中心為據點的特檢業務和以合作共建為增值的普檢業務,深度鏈接三甲醫院、醫聯體/醫共體和區域檢驗平台,上下延伸實現網絡縱深覆蓋;同時,公助力各抗疫防疫攻堅積極開展核酸檢測業務,一季度業績貢獻明顯,二季度臨牀送檢趨於常態。下半年,公司將按照五年戰略規劃的發展目標,持續推進從普檢業務到特檢業務,從技術引進到自主研發,從渠道代理到自產產品的價值鏈進階。

報吿期內,預計非經常性損益對公司淨利潤的影響金額約8000萬元-10000萬元,主要系公司參與投資的產業基金所投企業陸續上市,投資項目估值上升。

報吿期內,計提股權激勵費用約4000萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account